摘要
本研究主要分为两大部分,分别是IBS-D肝郁脾虚型病证症结合大鼠模型的建立与评价的初步研究和肠安I号方干预实验性IBS内脏高敏感大鼠的脑肠轴作用机制研究。
1 IBS-D肝郁脾虚型病证症结合大鼠模型的建立与评价的初步研究
目的：建立一种疾病-证候-症状相结合的IBS-D肝郁脾虚型大鼠模型。
方法：(1)模型建立方法：采用新生母子分离+慢性束缚+番泻叶灌胃法复制IBS-D肝郁脾虚型病证症结合大鼠模型。(2)模型评价方法：以结直肠扩张的疼痛阈值代表内脏高敏感性,评价”疾病”模型的建立；以旷场实验和血清D-木糖水平评价肝郁脾虚”证型”的建立；以排便粒数和稀便率评价腹泻”症状”的建立。
结果：(1)造模结束时,不同组间大鼠的体重变化存在统计学差异(F=10.132,p=0.000<0.05),与正常组比较,三因素组大鼠的体重增长量较少,存在统计学差异p<0.05)。(2)造模结束后,各组大鼠的疼痛阈值存在统计学差异(F=41.299,p=0.000<0.05),三因素组大鼠疼痛阈值明显降低,与正常组相比存在统计学差异(p<0.05)。(3)束缚结束后,各组大鼠总穿格数、站立次数、修饰次数存在统计学差异(p<0.05),与正常组相比,三因素组大鼠总穿格数、站立次数、修饰次数明显减少(p<0.05)。(4)各组大鼠血清D-木糖含量存在统计学差异(F=143.614,p=0.000<0.05),与正常组相比,三因素组大鼠血清D-木糖含量均显著下降(p<0.05)。(5)造模结束时,三因素组大鼠排便粒数与正常大鼠存在统计学差异(p<0.05)。
结论：应用SD大鼠进行新生母子分离+慢性束缚+番泻叶灌胃的复合造模,造模结束时三因素组大鼠体重增长速度减缓,结直肠扩张时疼痛阈值降低,内脏敏感性增高；旷场实验穿格数、站立次数及修饰次数均明显降低；血清D-木糖含量明显降低,小肠吸收功能下降；排便粒数及稀便率均明显升高,而结肠黏膜组织HE染色未见明显异常,符合IBS-D肝郁脾虚型疾病特点,可能是一种较好的研究中医药治疗IBS疗效机制的动物模型,但仍需要进一步的深入研究。
2肠安I号干预实验性IBS内脏高敏感大鼠的脑肠轴作用机制研究
目的：研究肠安Ⅰ号方对IBS内脏高敏感模型大鼠的作用机理,验证肠安Ⅰ号方改善IBS内脏高敏感性是基于脑和肠的双重作用的假设。
实验一、肠安Ⅰ号对IBS模型大鼠体重及内脏敏感性的影响
方法：(1)模型的建立与评价：采用慢性束缚应激结合游泳致疲劳法复制IBS内脏高敏感大鼠,以体重变化、内脏敏感性评价和病理组织学作为模型评价指标。(2)肠安Ⅰ号的干预作用：采用体重变化量评估体重的变化；大鼠结直肠扩张时大鼠腹壁回撤反射表现出3级反应时的压力阈值为疼痛阈值,以疼痛阈值评估大鼠内脏敏感性的变化。
结果：(1)造模结束时,不同组间大鼠的体重变化存在统计学差异(F=3.551,p=0.000<0.05),与正常组相比,模型组(p=0.019)大鼠的体重增长量明显减少；组间大鼠的疼痛阈值存在统计学差异(F=8.311,p=0.000<0.05),与正常组相比,模型组大鼠疼痛阈值明显下降(p<0.05)；各组大鼠结肠病理组织HE染色各组均未见明显改变。(2)灌药4、8、12天及治疗结束时,不同组间大鼠的体重变化均无统计学差异(p=0.730,0.804,0.137,0.444)。用药结束后,各组大鼠直肠扩张时的疼痛阈值存在统计学差异(x 2=30.933,p=0.000<0.05)；与正常组大鼠相比,模型组大鼠疼痛阈值明显降低(x 2=24.8472；p=0.0000<0.05)；与模型组相比,氟西汀组、肠安Ⅰ号高、中、低剂量组大鼠疼痛和阈值明显升高(x 2=8.7969,13.9562,12.7508,13.8110；p=0.0123,0.0009,0.0017,0.0010<0.05)。
实验二、肠安Ⅰ号对IBS模型大鼠结肠5-HT的影响
方法：采用结肠免疫组织化学染色法结合结肠粘膜积分光密度、积分光密度组织比的半定量分析评价大鼠结肠5-HT水平。
结果：用药结束后,各组大鼠结肠5-HT水平存在统计学差异(χ2=53.144,p=0.000<0.05)。与正常组大鼠相比,模型组大鼠结肠5-HT水平明显升高(x 2=38.2112；p=0.0000<0.05)。与模型组相比,得舒特组、肠安Ⅰ号高、中剂量组结肠5-HT水平显著下降(x 2=13.9439,14.6154,15.8966；p=0.0009,0.0004,0.0007<0.05)。
实验三、肠安Ⅰ号对IBS模型大鼠血清5-HT的影响
方法：采用酶联免疫吸附法测定大鼠血清5-HT水平。
结果：用药结束后,各组大鼠血清5-HT水平存在统计学差异(x 2=53.125,p=0.000<0.05)。与正常组大鼠相比,模型组大鼠血清5-HT水平升高(x 2=34.4853；p=0.0000<0.05)。与模型组相比,得舒特组、肠安Ⅰ号高、中剂量组大鼠血清5-HT水平显著下降(x 2=19.6384,16.0064,16.6231；p=0.0001,0.0003,0.0002<0.05)。
实验四、肠安Ⅰ号对IBS模型大鼠海马5-HT1a、BDNF基因表达的影响
方法：采用荧光定量实时PCR方法检测大鼠海马5-HT1a、BDNF mRNA基因表达水平。
结果：(1)用药结束后,各组大鼠海马5-HTla mRNA相对表达量存在统计学差异(x 2=59.606,p=0.000<0.05)。与正常组大鼠相比,模型组大鼠海马5-HT1a mRNA表达水平升高(x 2=40.5840；p=0.0000<0.05)。与模型组相比,肠安Ⅰ号高、中、低剂量组大鼠海马组织5-HT1a mRNA表达水平显著下降(x 2=11.6823,25.7737,14.5150；p=0.0029,0.0000,0.0007<0.05)。(2)用药结束后,各组大鼠海马BDNF mRNA的相对表达量存在统计学差异(x 2=45.914,p=0.000<0.05)。与正常组大鼠相比,模型组大鼠海马BDNF mRNA表达水平升高(x 2=36.7966；p=0.0000<0.05)。与模型组相比,氟西汀组、肠安Ⅰ号高、中、低剂量组大鼠海马BDNF mRNA表达水平升高下降(x 2=17.2327,10.9142,10.2546,13.6571；p=0.0002,0.0043,0.0059,0.0011<0.05)。
实验五、IBS模型大鼠内脏敏感性与结肠黏膜5-HT水平的相关性研究
目的：观察大鼠内脏敏感性与结肠黏膜5-HT水平的相关关系。
方法：相关性分析采用线性相关分析的方法,若数据符合双变量正态分布,使用Pearson相关系数r；若不符合,采用Spearman相关系数rs。p<0.05为差异有统计学意义。
结果：对所有大鼠的分析发现,疼痛阈值与结肠黏膜5-HT水平呈线性负相关关系(rs=-0.435,p=0.000),内脏敏感性与结肠5-HT水平呈正相关关系。
实验六、IBS模型大鼠内脏敏感性与血清5-HT水平的相关性研究
目的：观察大鼠内脏敏感性与血清5-HT水平的相关关系。
结果：对所有大鼠的分析发现,疼痛阈值与血清5-HT水平呈线性负相关关系(rs=-0.484,p=0.000),内脏敏感性与血清5-HT水平呈正相关关系。
实验七、IBS模型大鼠内脏敏感性与海马BDNF mRNA基因表达水平的相关性研究
目的：观察大鼠内脏敏感性与海马BDNF mRNA基因表达水平的相关关系。
结果：对所有大鼠的分析发现,疼痛阈值与海马BDNF mRNA基因表达水平呈线性负相关关系(rs=-0.550,p=0.000),内脏敏感性与海马BDNF mRNA基因表达水平呈正相关关系。
实验八、IBS模型大鼠内脏敏感性与海马5-HT1a mRNA基因表达水平的相关性研究
目的：观察大鼠内脏敏感性与海马5-HT1a mRNA基因表达水平的相关关系。
结果：对所有大鼠、模型组及用药组大鼠的分析发现,疼痛阈值与海马5-HT1a mRNA基因表达水平呈线性负相关关系(rs=-0.629,-0.773,-0.324,p=0.000,0.015,0.030),内脏敏感性与海马5-HT1a mRNA基因表达水平呈正相关关系。
结论：肠安I号的作用靶点部位涉及”脑-肠”两部分,可下调血清及结肠黏膜5-HT水平,下调海马组织中BDNF和5-HT1amRNA的表达；大鼠内脏敏感性的改变与血清及结肠黏膜5-HT水平、海马BDNF和5-HT1a呈线性相关关系,内脏敏感性的下调是以血清及结肠黏膜5-HT水平、海马BDNF和5-HT1a水平的下调为内在机制的,至于其相互间的复杂作用关系可能需要进一步的深入研究。
There are two parts in this paper, including preliminary study of establishing a new disease-syndrome-symptom integrated IBS animal model and exploration of brain-gut axis mechanism of Chang'anyihao in treatment of IBS animal model.
1 Preliminary study of establishing a new disease-syndrome-symptom integrated IBS animal model
Objective:To establish a new disease-syndrome-symptom integrated animal model of IBS-D due to syndrome of liver stagnation and spleen deficiency.
Methods:(1)Model establishment:we combined mother-infant separation, chronic restraint and senna gavage to establish a new animal model of IBS-D due to syndrome of liver stagnation and spleen deficiency. (2)Model evaluation:we used pain threshold indicating visceral hypersensitivity to evaluate "disease" model; open field test and serum D-xylose level to evaluate "syndrome" model; defecation grain number and loose stool rate to evaluate "symptom" model.
Results:(1)In the end, rat body weight change was significantly different (F=10.132, p=0.000<0.05). Compared with normal group, body weight gain of the three-factor rats was significantly decreased (p<0.05). (2)In the end, the pain threshold in different groups was significantly different (F=41.299,p=0.000<0.05), pain threshold of the three-factor rats was significantly declined compared with the normal group (p<0.05). (3)In the end, there was significant difference in open field test between groups (p<0.05). Compared with the normal group, total cross number, standing number and decoration number of three-factor rats were significantly dropped (p<0.05). (4)In the end, the serum D-xylose level of three-factor rats significantly went down (F=143.614, p=0.000<0.05). (5)In the end, defecation grain number and loose stool rate of the three-factor rats significantly went up (p<0.05). Conclusion:we combined mother-infant separation, chronic restraint and senna gavage and successfully established a new disease-syndrome-symptom integrated animal model of IBS-D due to syndrome of liver stagnation and spleen deficiency.
2 Exploration of brain-gut interaction mechanism of Chang'anyihao in treatment of IBS animal model
Objective:To explore the brain-gut axis mechanism of Chang'anyihao in treatment of IBS animal model.
Experiment 1.Chang'anyihao on body weight and visceral sensitivity
Methods:(1)Model establishment and evaluation:we combined chronic restraint stress and forced swimming to replicate IBS visceral hypersensitivity rat model and used weight change, visceral sensitivity and histopathological biopsy as evaluation indicators. (2)Chang'anyihao in treatment:we used body weight change to assess weight gain and pain threshold to assess changes in visceral sensitivity.
Conclusions:(1)In the end, weight changes between groups were significantly different (F=3.551,p=0.000<0.05). Compared with the normal group, body weight gain in the model group was significantly reduced (p=0.019). There were significant differences in pain threshold between groups (F=8.311,p=0.000<0.05). Compared with the normal group, pain threshold of the model group was significantly decreased (p<0.05). Histopathological HE staining in each group showed no significant changes. (2)On the 4th,8th and 12th day and at the end of treatment, the weight changes in different groups were not statistically different (p=0.730,0.804,0.137,0.444). In the end, there were significant differences in pain threshold between different groups (X 2=30.933,p=0.000<0.05). Compared with the normal group, pain threshold of the model group significantlty decreased (x 2=24.8472;p=0.0000<0.05). Compared with the model group, pain thresholds of fluoxetine group, Chang'anyihao high, medium and low-dose groups were significantly increased (x2=8.7969,13.9562,12.7508, 13.8110;p=0.0123,0.0009,0.0017,0.0010<0.05).
Experiment 2.Chang'anyihao on colon 5-HT level
Methods:We used immunohistochemical staining method to evaluate 5-HT level in rat colon.
Results:In the end,5-HT levels in rat colon were significantly different between groups (x2=53.144,p=0.000<0.05). Compared with the normal group, the 5-HT level in model group significantly went up (x2=38.2112;p=0.0000<0.05). Compared with the model group,5-HT levels of Schutte group, Chang'anyihao high and medium-dose groups significantly decreased (X 2=13.9439,14.6154,15.8966;p=0.0009,0.0004,0.0007<0.05).
Experiment 3.Chang'anyihao on serum 5-HT level of IBS rat model
Methods:We used ELISA to detect serum 5-HT level.
Results:In the end, serum 5-HT levels were significantly different between groups (x2=53.125,p=0.000<0.05). Compared with the normal group,5-HT level in the model group significantly went up (x2=34.4853;p=0.0000<0.05). Compared with the model group,5-HT levels of Schutte group, Chang'anyihao high and medium-dose groups significantly decreased (x 2=19.6384,16.0064,16.6231;p=0.0001,0.0003,0.0002<0.05).
Experiment 4. Chang'anyihao on hippocampal 5-HT1a and BDNF gene expression
Methods:We used fluorescent quantitative real-time PCR to detect 5-HTla and BDNF mRNA gene expression level in rat hippocampal.
Results:(1)In the end,5-HT1a mRNA expression levels were significantly different between groups (x2=59.606, p=0.000<0.05). Compared with the normal group,5-HTla mRNA expression level in the model group significantly went up (x2=40.5840;p=0.0000<00.05). Compared with the model group,5-HTla mRNA expression levels of Chang'anyihao high, medium and low-dose groups significantly decreased (x2=11.6823,25.7737,14.5150; p=0.0029,0.0000,0.0007<0.05). (2)In the end, BDNF mRNA expression levels were significantly different between groups (x2=45.914,p=0.000<00.05). Compared with the normal group, BDNF mRNA expression level in the model group significantly went up (x2=36.7966;p=0.0000<0.05). Compared with the model group, BDNF mRNA expression levels of fluoxetine group, Chang'anyihao high, medium and low-dose groups significantly decreased (x2=17.2327,10.9142,10.2546,13.6571;p=0.0002,0.0043,0.0059,0.0011<0.05).
Experiment 5.Correlation between visceral sensitivity and colon 5-HT level
Objective:To investigate the relationship between visceral sensitivity and colon 5-HT level.
Methods:We used Spearman correlation to assess the correlations between two parameters, differences were considered significant at p<0.05.
Results:There was a linear negative correlation between pain threshold and colon 5-HT level (rs=-0.435,p=0.000).
Experiment 6.Correlation between visceral sensitivity and serum 5-HT level
Objective:To investigate the relationship between visceral sensitivity and serum 5-the HT level.
Results:Pain threshold and serum 5-HT level showed a linear negative correlation (rs=-0.484, p=0.000).
Experiment 7.Correlation between visceral sensitivity and 5-HT1a mRNA level in rat hippocampal
Objective:To investigate correlation between visceral sensitivity and BDNF mRNA expression level in rat hippocampal.
Results:Pain threshold and 5-HT1a mRNA level in rat hippocampal showed a linear negative correlation (rs=-0.550, p=0.000).
Experiment 8. Correlation between visceral sensitivity and BDNF mRNA level of rat hippocampal
Objective:To investigate the correlations between visceral sensitivity in rats and hippocampal BDNF mRNA gene expression level.
Results:Pain threshold and 5-HT1a mRNA level in rat hippocampal showed a linear negative correlation in all rats, model rats and treated rats (rs=-0.629,-0.773,-0.324,p=0.000,0.015, 0.030).
Conclusion:Chang'anyihao can reduce serum and colon 5-HT levels and lower BDNF and 5-HT1a mRNA expression in rat hippocampus.
引文
[1]Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders Gastroenterology,2006,130(5):1480-1491.
[2]中华医学会消化病学分会胃肠动力组.肠易激综合征诊断和治疗的共识意见(2007,长沙).中华消化杂志,2008,28(1)：38-40.
[3]Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am,2011, 40(1):1-10.
[4]潘国宗,鲁素彩,柯美云,等.北京地区肠易激综合征的流行病学研究：一个整群、分层、随机的调查.中华流行病学杂志,2000,21(1)：26-28.
[5]熊理守,陈星湖,陈惠新,等.广东省社区人群肠易激综合征的流行病学研究.中华医学杂志,2004,84(4)：278-281.
[6]Lovell RM, Ford AC. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol.2012 Mar 15. PMID:22426087.
[7]Katiraei P, Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J Gastroenterol,2011,17(23): 2791-800.
[8]Walker FA, Roy-byml PP, Kalon WJ, et al. Irritable bowel syndrome and psychiatricillness. Am J Psychiatry,1990,147(5):565-572.
[9]Sugaya N, Nomura S. Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome. Bio Psycho Social Medicine,2008,2:9-15.
[10]Marshall JK, Thabane M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut,2010,59(5):605-11.
[11]胡品津.从脑-肠互动的高度认识肠易激综合征.中华消化杂志,2003,23(5)：261-262.
[12]Kennedy PJ, Clarke G, Quigley EM, et al. Gut memories:towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev,2012,36(1):310-40.
[13]Mazurak N, Seredyuk N, Sauer H, Teufel M, Enck P. Heart rate variability in the irritable bowel syndrome:a review of the literature. Neurogastroenterol Motil,2012, 24(3):206-16.
[14]程晓雯,郑清华,李小玲,等.血管活性肠肽与某些胃肠动力紊乱性疾病的内在关联研究进展.中国全科医学杂志,2012,15(3)：237-241.
[15]霍涛,胡团敏,黄思付.黄术灌肠液对腹泻型肠易激综合征大鼠肥大细胞与P物质的影响.世界华人消化杂志,2012,20(3)：219-223.
[16]张瑜,卜平.IBS患者肠黏膜P物质的表达及其与焦虑、抑郁的相关性研究.中外健康文摘,2010,7(27)：371-373.
[17]杨江升,徐珊,申屠利明,等.宁肠汤对腹泻型肠易激综合征模型大鼠酪神经肽的影响.中华中医药学刊,2010,28(3)：609-611.
[18]李铁男,王兵,刘影,等.菝葜提取物对肠易激综合征大鼠血浆SP, CGRP含量的影响.中医药学报,2011,39(4)：26-28.
[19]潘相学.疏肝饮对肝郁脾虚大鼠CRH和NT的调节作用.中国现代药物应用,2010,4(12)：24-27.
[20]王敬东.脑-肠互动在肠易激综合征发病中的作用.世界华人消化杂志,14(34)：3299-3301.
[21]Fukudo S, Nomura T, Muranaka M, et al. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome. A preliminary study. J Clin Gastroenterol,1993,17(2):133-141.
[22]董文珠,邹多武,李兆申,等.肠易激综合征患者内脏高敏性的机制研究.中华消化杂志,2004,24(1)：18-22.
[23]Wood JD, Liu S, Drossman DA, et al. Anti-enteric neuronal antibodies and the irritable bowel syndrome. J Neurogastroenterol Motil,2012,18(1):78-85.
[24]Larauche M, Mulak A, Tache Y.Stress-related alterations of visceral sensation:animal models for irritable bowel syndrome study. J Neurogastroenterol Motil,2011, 17(3):213-34.
[25]Vicario M, Alonso C, Guilarte M, et al. Chronic psychosocial stress induces reversible mitochondrial damage and corticotropin-releasing factor receptor type-1 upregulation in the rat intestine and IBS-like gut dysfunction. Psychoneuroendo-crinology,2012, 37(1):65-77.
[26]Zhang R, Zou N, Li J, et al. Elevated expression of c-fos in central nervous system correlates with visceral hypersensitivity in irritable bowel syndrome (IBS):a new target for IBS treatment. Int J Colorectal Dis,2011,26(8):1035-44.
[27]Larsson MB, Tillisch K, Craig AD, et al. Brain responses to visceral stimuli reflect visceral sensitivity thresholds in patients with irritable bowel syndrome. Gastroenterology, 2012,142(3):463-472.
[28]Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut.2012,61(5):685-94.
[29]Piche M, Bouin M, Arsenault M, et al. Decreased pain inhibition in irritable bowel syndrome depends on altered descending modulation and higher-order brain processes.Neuroscience,2011,195:166-75.
[30]Ibeakanma C, Ochoa-Cortes F, Miranda-Morales M, et al. Brain-gut interactions increase peripheral nociceptive signaling in mice with postinfectious irritable bowel syndrome.Gastroenterology,2011,141(6):2098-2108.
[31]Niddam DM, Tsai SY, Lu CL, et al. Reduced hippocampal glutamate-glutamine levels in irritable bowel syndrome:preliminary findings using magnetic resonance spectroscopy.Am J Gastroenterol,2011,106(8):1503-11.
[32]Feng B, La JH, Schwartz ES, et al. Neural and neuro-immune mechanisms of visceral hypersensitivity in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol,2012,PMID:22403791.
[33]Fukudo S, Nomura T, Muranaka M, et al. Brain-gut response to stress and cholinergic stimulation in irritable bowel syndrome.J Clin Gastroenterol,1993,17(2):133-41.
[34]Blomhoff S, Spetalen S, Jacobsen MB, et al. Intestinal reactivity to words with emotional content and brain information processing in irritable bowel syndrome. Dig Dis Sci,2000, 45(6):1160-5.
[35]Sagami Y, Shimada Y, Tayama J, et al. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut,2004,53(7):958-64.
[36]沈骏,诸琦,袁耀宇,等.肠易激综合征患者脑部痛觉功能区域的变化.胃肠病学和肝病学杂志,2005,14(2)：167-171.
[37]O'Malley D, Quigley EM, Dinan TG, et al. Do interactions between stress and immune responses lead to symptom exacerbations in irritable bowel syndrome? Brain Behav Immun,2011,25(7):1333-41.
[38]Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut,2004,53(8):1096-101.
[39]Akbar A, Yiangou Y, Facer P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut, 2008,57(7):923-9.
[40]Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology,2007, 132(1):26-37.
[41]Hughes PA, Brierley SM, Martin CM, et al. TRPVI-expressing sensory fibres and IBS: links with immune function. Gut,2009,58(3):465-6.
[42]Ohashi K, Sato Y, Kawai M, Kurebayashi Y. Abolishment of TNBS-induced visceral hypersensitivity in mast cell deficient rats. Life Sci,2008,82(7-8):419-23.
[43]Buhner S, Li Q, Vignali S, et al. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome.Gastroenterology, 2009,137(4):1425-34.
[44]Arevalo F, Aragon V, Montes P, et al. Increase of intraepithelial lymphocytes in patients with irritable bowel syndrome. Rev Gastroenterol Peru,2011,31(4):315-8.
[45]Ohman L, Lindmark AC, Isaksson S, et al. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients.Eur J Gastroenterol Hepatol,2012, 24(4):398-405.
[46]Vivinus-Nebot M, Dainese R, Anty R, et al.Combination of allergic factors can worsen diarrheic irritable bowel syndrome:role of barrier defects and mast cells.Am J Gastroenterol,2012,107(1):75-81.
[47]Klooker TK, Braak B, Koopman KE, et al.The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome.Gut,2010,59(9):1213-21.
[48]P Moayyedi,A C Ford,N J Talley,et al.The efficacy of probiotics in the treatment of irritable bowel syndrome:a systematic review.Gut,2010,59:325-332.
[49]Pimentel M, Park S, Mirocha J, Kane SV, Kong Y.The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome:a randomized trial.Ann Intern Med,2006,145(8):557-63.
[50]Zhu WL, Li Y, Wei HF, et al. Effect of electro-acupuncture at different acupoints on neuropeptide and somatostatin in rat brain with irritable bowel syndrome.Chin J Integr Med,2012,18(4):288-92.
[51]Suarez-Hitz KA, Otto B, Bidlingmaier M,et al. Altered psychobiological responsiveness in women with irritable bowel syndrome. Psychosom Med,2012,74(2):221-31.
[52]Tillisch K, Labus J, Nam B, et al.Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome:a pilot study.Aliment Pharmacol Ther,2012,35(3):360-7.
[53]El-Salhy M, Gundersen D, Ostgaard H, et al.Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci, 2012,57(4):873-8.
[54]Dlugosz A, Zakikhany K, Muschiol S, et al.Infection of human enteroendocrine cells with Chlamydia trachomatis:a possible model for pathogenesis in irritable bowel syndrome.Neurogastroenterol Motil,2011,23(10):928-34.
[55]Mykletun A, Jacka F, Williams L, et al.Prevalence of mood and anxiety disorder in self reported irritable bowel syndrome (IBS). An epidemiological population based study of women.BMC Gastroenterol,2010,10:88.
[56]Butt AS, Salih M, Jafri W, et al. Irritable bowel syndrome and psychiatric disorders in pakistan:a case control study. Gastroenterol Res Pract,2012; 2012:291452.
[57]Park H, Lim S. Frequency of irritable bowel syndrome, entrance examination-related stress, mental health, and quality of life in high school students. Gastroenterol Nurs,2011, 34(6):450-8.
[58]Jones M, Koloski N, Boyce P, et al.Pathways connecting cognitive behavioral therapy and change in bowel symptoms of IBS.J Psychosom Res.2011,70(3):278-85.
[59]Mahvi-Shirazi M, Fathi-Ashtiani A, Rasoolzade-Tabatabaei SK, et al.Irritable bowel syndrome treatment:cognitive behavioral therapy versus medical treatment. Arch Med Sci. 2012 Feb 29;8(1):123-9.
[60]Gaylord SA, Palsson OS, Garland EL, et al. Mindfulness training reduces the severity of irritable bowel syndrome in women:results of a randomized controlled trial. Am J Gastroenterol,2011,106(9):1678-88.
[61]Deechakawan W, Cain KC, Jarrett ME, et al. Effect of Self-Management Intervention on Cortisol and Daily Stress Levels in Irritable Bowel Syndrome. Biol Res Nurs,2011 Jul 15. PMID:21765120.
[62]Halpert A, Rybin D, Doros G.Expressive writing is a promising therapeutic modality for the management of IBS:a pilot study.Am J Gastroenterol.2010,105(11):2440-8.
[63]Franks I. IBS:A polymorphism in TNFSF15 is associated with susceptibility to IBS. Nat Rev Gastroenterol Hepatol.2011,8(8):419.
[64]Basu PP, Shah NJ, Krishnaswamy N, et al. Prevalence of restless legs syndrome in patients with irritable bowel syndrome. World J Gastroenterol,2011,17(39):4404-7.
[65]Yilmaz A, Cumurcu BE, Tasliyurt T, et al. Role of psychiatric disorders and irritable bowel syndrome in asthma patients.Clinics (Sao Paulo),2011,66(4):591-7.
[66]吴立平,史维.功能性胃肠病的根源：脑肠轴神经系统记忆假说.世界华人消化杂志,2006,14(26)：2617-2619.
[67]Kearney DJ. Mindfulness meditation for women with irritable bowel syndrome-evidence of benefit from a randomised controlled trial. Evid Based Nurs.2012, PMID:22531145.
[68]Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine-a randomized controlled trial. JAMA 1998;280:1585-1589.
[69]Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.:CD004116.pub2. DOI:10.1002/14651858.CD004116.pub2. Cochrane.
[70]Manheimer E, Wieland LS, Cheng K, et al. Acupuncture for Irritable Bowel Syndrome: Systematic Review and Meta-Analysis. Am J Gastroenterol,2012 Apr 10.PMID:22488079.
[1]Williams CL, Villar GR, Peterson JM, et al. Stress-induced changes in intestinal transit in the rats:A model for irritable bowel syndrome. Gastroenterology,1988,94(3):611-621.
[2]Gue M, Del Rio-Lacheze C, Eutamene H, et al. Stress-induced visceral hypersensitivity to rectal distension in rats:role of CRF and mast cells. Neurogastroenterol Motil,1997, 9(4):271-279.
[3]严茂祥,占宏伟,陈芝芸,等.游泳致疲劳对大鼠血和结肠组织中胃肠激素的影响.浙江中医学院学报,2000,24(4)：44-45,82.
[4]Erckenbrecht JF, Butsch BH, Enck P. Physical stress increases, Mental stress decreases the gastrocolonic response to eating.Gastroenterol,1989,96.A141.
[5]赵晓林,李思,贾漪涛,等.滋补肝肾方药对慢性激怒大鼠下丘脑肝脏核糖体聚态的影响.中国中医基础杂志,1997,3(5)：28-30,33.
[6]叶蔚,陈芝芸,占宏伟,等.慢性激怒应激对大鼠血和结肠粘膜前列腺素E2、环核苷酸的影响.浙江中医学院学报,2000,24(4)：45-46.
[7]Winston J H, Xu G, Sarna S K. Adrenergic stimulation mediates visceral hypersensitivity to colorectal distension following heterotypic chronic stress. Gastroenterology,2010, 138(1):294.
[8]吕红,王伟岸,钱家鸣.传统束缚应激动物模型内脏感觉的新评价.胃肠病学和肝病学杂志,2005,14(2)：111-113.
[9]Tache Y, Garrick T, Raybouid H.Central nervous system action of peptides to influence gastrointestinal motor function. Gastroenterology,1990,98(2):517-518.
[10]Coutinho SV, Plotsky PM,Sablad M,et al.Neonatal maternal separation alters stress-induced responses to viscera somatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol,2002,282(2):G307-316.
[11]Barbara G, Vallanee BA,Collins SM.Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastoenterology,1997,113(4):1224-1232.
[12]郭敏,李延青,于秀娟,等.大鼠急性肠道感染后肠功能紊乱动物模型的建立.山东大学学报(医学版),2006,44(6)：586-589.
[13]Collions SM, McHugh K, Jacobson K, et al.Previous inflammation alters the response of the rat colon to stress.Gastroenterology,1996,111 (6):1509-1515.
[14]AL-Chaer ED,Kawasaki M, Pasricha PJ, et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterolgoy,2000,119(5):1276-1285.
[15]Bourdu S, Dapoigny M,Chapuy E,et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology,2005,128(7):1996-2008.
[16]Traub RJ, Tang B, Ji Y, et al. A rat model of chronic postinflammatory visceral pain induced by deoxycholic acid. Gastroenterology,2008,135(6):2075-2083.
[17]陈锡强,毕宏征,李祖伦.直肠注射醋酸致大鼠内脏高敏感性的实验研究.山西中医学院学报,2005,6(1)：52-53.
[18]Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome.Gastroenterology,2002,122(7):1778-1783.
[19]张艳丽,王承党.葡聚糖硫酸钠结肠炎模型的制作方法、特点和影响因素.胃肠病学,2006；11(1)：56-58.
[20]王承党,郑雪雁,郑玮玮.结肠黏膜低度炎症对大鼠内脏感觉的影响.世界华人消化杂志,2009,17(16)：1621-1625.
[21]AL-Chaer ED,Kawasaki M, Pasricha PJ,et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development Gastroenterolgoy,2000,119 (5):1276-1285.
[22]Scott RB, Tan DT,Miampamba M, et al.Anaphylaxis-induced alterations intestinal motility:role of extrinsic neural pathways.Am-J-Physiol,1998,275(4 Pt 1):G812-821.
[23]徐启旺,钱家鸣,窦君,等.细菌潜生体相关的肠易激综合征动物模型的建立及细菌潜生体在肠易激综合征中的意义.胃肠病学,2003,8(supplement):A6.
[24]刘俊康,陈杰,吴小兰,徐启旺.细菌潜生体相关的IBS动物模型建立实验研究.胃肠病学和肝病学杂志2007；16：243-246.
[25]刘俊康,闫国华,章荣华,等.细菌潜生体与IBS关系的初步研究.第三军医大学学报,2007,29(4)：321-323.
[26]Maxwell PR, Rink E, Kumar D, et al. Antibiotics increase functional abdominal symptoms[J]. Am J Gastroenterol,2002,97(1):104-108.
[27]De-Felipe C, Herrero JF, O'Brien JA. et al. Altered nociception analgesia andaggression in mice lacking the receptor for substance P. Nature,1998,392 (6674):394-397.
[28]Chen JJ,Li Z,Pan H,et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter:abnormal intestinal motility and the expression of cation transporters. J Neurosci,2001,21:6348-6361.
[29]彭丽华,孙刚,杨云生.便秘型肠易激综合征新概念模型的建立.世界华人消化杂志,2004,12：112-116.
[30]李丹,吕妍,唐方.腹泻型肠易激综合征大鼠模型的建立.天津中医药,2009,26(3),240-242.
[31]Naliboff BD, Chang L, Munakata J, et al. Towards an integrative model of irritable bowel syndrome. Prog Brain Res,2000,122:413-423.
[32]朱力阳,彭成,谢晓芳,王嫣虹.化学刺激引起的两种大鼠内脏高敏感性模型的建立.中国药理学通报,2010,26(2),267-270.
[33]唐洪梅,何嘉仑,闫雪,等.醋酸刺激加母婴分离致大鼠肠易激综合征模型的建立及评价.中医研究,2010,23(10)：19-21.
[34]王伟岸,钱家鸣,潘国宗,等.脑-肠互动指向性条件应激肠易激综合征动物模型的建立.中华消化杂志,2004,24(10),590-593.
[35]钱锋,卜平.痛泻要方干预大鼠肠易激综合征肝郁脾虚证的作用及机制.苏州大学学报(医学版),2010,30(6)：1179-1181,1238.
[36]徐珊,晋丽君,谭涛,等.乐胃饮对脾虚型IBS兔胃肠激素及氧自由基的影响.浙江中医药大学学报,2008,32(5)：590-594.
[37]王运东,张俊秀,牛小平,等.C-Fos在腹泻型肠易激综合征大鼠模型脊髓中的表达及意义.国际消化病杂志,2010,30(1)：50-53.
[38]李俊霞,刘新光,谢鹏雁,等.钙离子在大鼠结肠平滑肌运动中作用机制的研究.中华内科杂志,2000,39(9)：588-591.
[39]旺建伟,赵文静,历凯,等.痛泻要方对小鼠胃肠运动双向调节作用的研究.中国中医药信息杂志,2008,15(8)：32-34.
[40]胡瑞,唐方.胃肠安丸对IBS-D大鼠血清NO,5-HT及结肠组织SP,MC的影响.中国中药杂志,2009,34(23)：3073-3077.
[41]韩炜,陈建,李君曼,等.肥大细胞及其雌激素受体在肠易激综合征发病机制中的作用.中华消化内镜杂志,2003,20(2)：100-102.
[1]熊理守,陈旻湖,陈惠新,等.社区人群中肠易激综合征的症状学特征.胃肠病学2004,9(5)：277-279.
[2]汤小龙.肠易激综合征腹泻型的证型分布规律及其相关性研究[D].南京：南京中医药大学第一临床医学院,2010.
[3]上海市双歧三联活菌协作组,双歧三联活菌治疗肠易激综合征的临床多中心研究,上海医学,2004,27(10)：728-731.
[4]陈淑洁.IBS的生活质量研究.国外医学.消化系统疾病分册.2002,22(1)：25-27.
[5]王承党,陆岽,吴婷,等.不同药物治疗肠易激综合症的临床疗效.胃肠病学,2003,8(5)：272-275.
[6 Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine-a randomized controlled trial. JAMA,1998:280:1585-1589.
[7]Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.:CD004116.pub2. DOI:10.1002/14651858.CD004116.pub2. Cochrane.
[8]Naliboff BD, Chang L, Munakata J, et al. Towards an integrative model of irritable bowel syndrome. Prog Brain Res,2000,122:413-423.
[9]滕茜华,李德勤.不同浸出时间和方法对番泻叶有效成分的影响.时珍国药研究,1991,2(2)：75-80.
[10]Coutinho SV, Plotsky PM,Sablad M,et al. Neonatal maternal separation alters stress-induced responses to viscera somatic nociceptive stimuli in rat. Am J Physiol Gastrointest Liver Physiol,2002,282(2):G307-316.
[11]岳利峰,丁杰,陈家旭,等.肝郁脾虚证大鼠模型的建立与评价.北京中医药大学学报,2008,31(6)：396-400.
[12]陆佰荣,李林.脾虚动物模型研制的进展.齐齐哈尔医学院学报,2006,27(2)：194-195.陈学习.脾虚证动物模型复制方法研究概况、评价与思考.中国当代医药,2010,17(33)：5-6,47.
[13]王新,韩月东,吴汉平,等.番泻叶提取物对小鼠胃肠运动及其组织形态学的影响.中国中西医结合杂志,2001,21(6)：66-65.
[14]高哗,朱艳华,贺微,等.番泻叶的药用研究进展.中国药学刊,2006,24(11)：2145-2146.
[15]林媚,唐旭东,王凤云.肠安Ⅰ号对实验性腹泻型肠易激综合征大鼠结肠黏膜NF-κB的影响.中华中医药杂志,2010,25(12)：2339-2341.
[16]费晓燕,谢建群,郑昱,等.疏肝饮对腹泻型肠易激综合征模型大鼠胃动素和胆囊收缩素的影响.上海中医药杂志.2008,42(4)：63-65.
[17]王迎寒,陈光晖,刘玉玲,等.健脾化湿颗粒对IBS模型大鼠结肠NO和NOS的影响.承德医学院学报,2010,27(2)：129-131.
[18]AL-Chaer ED, Kawasaki M, Pasricha PJ, et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development Gastroenterolgoy,2000,119 (5):1276-1285.
[19]李冬华,朱飞鹏,李珊珊,等.疏肝健脾法调控肠易激综合征动物模型胃肠激素水平的研究.中国实验方剂学杂志,2008,14(7)：20-23.
[20]李延青,郭玉婷,左秀丽,等.肠易激综合征内脏感觉过敏动物模型的建立.胃肠病学和肝病学杂志,2003,12(4)：332-335.
[21]李华燕,张涛,潘锋.痛泻要方对腹泻型肠易激综合征大鼠结肠肥大细胞及辣椒素受体的影响.中国中医药科技,2011,18(5)：400-402.
[22]李冬华,朱飞鹏,李珊珊,等.疏肝健脾法调控肠易激综合征动物模型胃肠激素水平的研究.中国实验方剂学杂志,2008,14(7)：20-23.
[23]谢建群,陆雄,龚丽萍,等.健脾温中法对脾胃虚寒型肠易激综合征模型大鼠血管活性肠肽影响的实验研究.上海中医药大学学报,2003,17(4)：49-51.
[24]白霞,谢小磊,李梦,等.加味四逆散对肠易激综合征大鼠不同脑区核团c-fos蛋白表达的影响.中国中医基础医学杂志,2010,16(1)：40-41.
[25]吴美玉,胡团敏,郑溪水.黄术灌肠液对腹泻型肠易激综合征大鼠结肠黏膜VIP表达的影响.世界华人消化杂志,2010,18(28)：2966-2970.
[26]林媚,唐旭东,王凤云.肠安Ⅰ号对实验性腹泻型肠易激综合征大鼠结肠黏膜NF-κB的影响.中华中医药杂志(原中国医药学报),2010,25(12)：2339-2341.
[27]Walker FA, Roy-byml PP, Kalon WJ, et al. Irritable bowel syndrome and psychiatricillness. Am J Psychiatry,1990,147(5):565-572.
[28]Sugaya N, Nomura S. Relationship between cognitive appraisals of symptoms and negative mood for subtypes of irritable bowel syndrome. Bio Psycho Social Medicine, 2008,2:9-15.
[29]李延青,郭玉婷.肠易激综合征的动物模型研究.胃肠病学和肝病学杂志,2004,13(4)：435-439.
[1]Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders Gastroenterology,2006,130(5):1480-1491.
[2]中华医学会消化病学分会胃肠动力组.肠易激综合征诊断和治疗的共识意见(2007,长沙).中华消化杂志,2008,28(1)：38-40.
[3]Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am,2011, 40(1):1-10.
[4]潘国宗,鲁素彩,柯美云,等.北京地区肠易激综合征的流行病学研究：一个整群、分层、随机的调查.中华流行病学杂志,2000,21(1)：26-28.
[5]熊理守,陈星湖,陈惠新,等.广东省社区人群肠易激综合征的流行病学研究.中华医学杂志,2004,84(4)：278-281.
[6]Lovell RM, Ford AC. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis. Clin Gastroenterol Hepatol.2012 Mar 15. PMID:22426087.
[7]Howard R. Mertz, M.D. Irritable Bowel Syndrome. N Eng J Med 2003; 349:2136-46.
[8]Hulisz D. The burden of illness of irritable bowel syndrome:current challenges and hope for the future. J Manag Care Pharm.2004 Jul-Aug; 10(4):299-309.
[9]Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom. Digestion.1999; 60:77-81.
[10]Katiraei P, Bultron G. Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome. World J Gastroenterol,2011, 17(23):2791-800.
[11]Kennedy PJ, Clarke G, Quigley EM, et al. Gut memories:towards a cognitive neurobiology of irritable bowel syndrome. Neurosci Biobehav Rev,2012,36(1):310-40.
[12]Larauche M, Mulak A, Tache Y. Stress-related alterations of visceral sensation:animal models for irritable bowel syndrome study. J Neurogastroenterol Motil,2011, 17(3)：213-34.
[13]Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine-a randomized controlled trial. JAMA 1998; 280:1585-1589.
[14]Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.:CD004116.pub2. DOI:10.1002/14651858.CD004116.pub2. Cochrane.
[15]林媚,唐旭东,王风云,等.含有低浓度肠安Ⅰ号制作的安慰剂对腹泻型IBS大鼠内脏高敏感性的影响.上海中医药杂志,2010,44(5)：88-90.
[16]林媚,唐旭东,王凤云,肠安Ⅰ号及低浓度原药对照安慰剂的实验药效学研究.深封中西医结合杂志,2009,19(5)：273-278.
[17]林媚,唐旭东,王凤云.肠安Ⅰ号对实验性腹泻型肠易激综合征大鼠结肠黏膜NF-κB的影响.中华中医药杂志(原中国医药学报),2010,25(12)：2339-2341.
[18]林媚,唐旭东.肠安Ⅰ号及安慰剂对腹泻型肠易激综合征大鼠免疫功能的影响.深封中西医结合杂志,2009,19(6)：333-335.
[19]卞立群.肠安Ⅰ号方治疗IBS-D的临床疗效评价暨临床疗效评价指标的比较研究[D].北京：中国中医科学院研究生院,2011.
[20]Crowell MD, Wessinger SB.5-HT and the brain-gut axis:opportunities for pharmacologic intervention.Expert Opin Investig Drugs.2007 Jun; 16(6):761-5.
[21]Yu YB, Zuo XL, Zhao QJ, et al. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome.Gut.2012 May;61(5):685-94.
[22]严茂祥,占宏伟,陈芝芸,等.游泳致疲劳对大鼠血和结肠组织中胃肠激素的影响.浙江中医学院学报,2000,24(4)：44-45,82.
[23]Erckenbrecht JF, Butsch BH, Enck P. Physical stress increases, Mental stress decreases the gastrocolonic response to eating. Gastroenterol,1989,96.A141.
[24]Williams CL, Villar GR, Peterson JM, et al. Stress-induced changes in intestinal transit in the rats:A model for irritable bowel syndrome. Gastroenterology,1988,94 (3):611-621.
[25]AL-Chaer ED, Kawasaki M, Pasricha PJ,et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development. Gastroenterolgoy,2000,119 (5):1276-1285.
[26]李延青,郭玉婷,左秀丽,等.肠易激综合征内脏感觉过敏动物模型的建立.胃肠病学和肝病学杂志,2003,12(4)：332-335.
[27]李延青,郭玉婷.肠易激综合征的动物模型研究.胃肠病学和肝病学杂志,2004,13(4)：435-439.
[28]吕红,王伟岸,钱家鸣.传统束缚应激动物模型内脏感觉的新评价.胃肠病学和肝病学杂 志,2005,14(2)：111-113.
[1]严茂祥,占宏伟,陈芝芸,等.游泳致疲劳对大鼠血和结肠组织中胃肠激素的影响.浙江中医学院学报,2000,24(4)：44-45,82.
[2]Erckenbrecht JF, Butsch BH, Enck P. Physical stress increases, Mental stress decreases the gastrocolonic response to eating. Gastroenterol,1989,96.A141.
[3]Williams CL, Villar GR, Peterson JM, et al. Stress-induced changes in intestinal transit in the rats:A model for irritable bowel syndrome. Gastroenterology,1988,94 (3):611-621.
[4]Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain.Neurogastroenterol Motil.2010 Mar;22(3):312-e84.
[5]袁盛榕.药理学实习教程.北京：世界图书出版公司,1994：13.
[6]AL-Chaer ED,Kawasaki M, Pasricha PJ,et al. A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development Gastroenterolgoy,2000,119 (5):1276-1285.
[7]Grundy D. What activates visceral afferents? Gut.2004 Mar;53 Suppl 2:ii5-8.
[8]Keszthelyi D, Troost FJ, Simren M, Ludidi S, Kruimel JW, Conchillo JM, Masclee AA. Revisiting concepts of visceral nociception in irritable bowel syndrome. Eur J Pain.2012 Apr 13. doi:10.1002/j.1532-2149.2012.00147.x. PMID:22504901.
[9]董明,郭欣欣,吴焕淦,等.内脏高敏感发生机制的研究进展.中国医药生物技术,2012,7(1)：54-58.
[10]林媚,唐旭东,王风云,等.含有低浓度肠安Ⅰ号制作的安慰剂对腹泻型IBS大鼠内脏高敏感性的影响.上海中医药杂志,2010,44(5)：88-90.
[11]林媚,唐旭东,王凤云,肠安Ⅰ号及低浓度原药对照安慰剂的实验药效学研究.深封中西医结合杂志,2009,19(5)：273-278.
[12]林媚,唐旭东,王凤云.肠安Ⅰ号对实验性腹泻型肠易激综合征大鼠结肠黏膜NF-κB的影响.中华中医药杂志(原中国医药学报),2010,25(12)：2339-2341.
[13]林媚,唐旭东.肠安Ⅰ号及安慰剂对腹泻型肠易激综合征大鼠免疫功能的影响.深封中西医结合杂志,2009,19(6)：333-335.
[14]唐洪梅,黄樱华,李得堂,等.肠激安方对腹泻型肠易激综合征模型大鼠T淋巴细胞和5-羟色胺的影响.广州中医药大学学报,2009,26(2)：164-168,200.
[15]丛军,蔡淦,张正利,等.肠吉泰对腹泻型肠易激综合征大鼠结肠肥大细胞变化和5-羟色胺表达的影响.安徽中医学院学报,2010,29(6)：47-51.
[16]迟雁,刘新光,李江.5-轻色胺4受体在调节应激大鼠内脏敏感性中的作用.中华消化杂志,2004,24：533-536.
[17]李运红,朱晓荫,徐肇敏.腹泻型肠易激综合征患者结肠私膜5-羟色胺和5-羟色胺3受体的研究.胃肠病学杂志,2006,11：477-480.
[18]祝淑贞,周福生.5-HT与肠易激综合征发病的内在相关性.临床消化病杂志,2004,16：229-230.
[19]陈文科,邹益友,李富军,等.肠易激综合征精神心理因素、肠粘膜肥大细胞及5-羟色胺的变化.世界华人消化杂志,2007,15：46-50.
[20]Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.Gastroenterology,2004,126(7):1657-64.
[21]Kerckhoffs AP, Ter Linde JJ, Akkermans LM, Samsom M. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients. Neurogastroenterol Motil,2008,20(8):900-7.
[22]Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation-and diarrhea-predominant irritable bowel syndrome. Gastroenterology.2006,130(1):34-43.
[23]Moskwa A, Chojnacki J, Stec-Michalska K, et al. Serum serotonin concentration and urine 5-hydroxyindole acetic acid excretion in patients with irritable bowel syndrome. Pol Merkur Lekarski,2007,22(131):366-8.
[24]Sikander A, Rana SV, Sinha SK, et al. Altered serotonin signaling in IBD, diarrhea-predominant IBS and microscopic colitis. Indian J Gastoenterol,2007, 26(Suppl2):A42.
[25]詹丽杏,李兆申,邹多武,等.肠易激综合征患者血浆5-HT、5-HIAA浓度改变.基础医学与临床(增刊),2003,23：95.
[26]宋士一,王德山,王艳杰,等.眼针对肠易激综合征模型大鼠结肠组织和血清5-HT、5-HIAA的影响.上海针灸杂志,2010,29(6)：339-341.
[27]张树卿,查安生,石美雅,等.逍遥煎剂对腹泻型肠易激综合征大鼠血清5-HT、NO的影响.河南中医,2011,31(9)：986-988.
[28]王垂杰,包艳莉,李玉锋.痛泻要方对肠易激综合征模型大鼠血清5-HT和NO影响的实验研究.世界中西医结合杂志,2009,4(11)：776-779.
[29]石君杰,戴玉英,王海云,等.逍遥散对肠易激综合征大鼠内脏高敏感性和血清5-HT的影响.江苏中医药,2008,9(10)：109-111.
[30]Temel Y, Boothman LJ, Blokland A, et al. Inhibition of 5-HT neuron activity and induction of depressive-like behavior by high-frequency stimulation of the subthalamic nucleus. Proc Natl Acad Sci USA,2007,104(43):17087-92.)
[31]Nakajima K, Obata H, Ito N, et al. The nociceptive mechanism of 5-hydroxytryptamine released into the peripheral tissue in acute inflammatory pain in rats. Eur J Pain,2009, 13(5):441-7.
[32]Kato K, Kikuchi S, Konno S, Sekiguchi M. Participation of 5-hydroxytryptamine in pain-related behavior induced by nucleus pulposus applied on the nerve root in rats. Spine (Phila Pa 1976).2008,33(12):1330-6.
[33]Hannon J, Hoyer D. Serotonin receptors and systems:endless diversity? Acta Biol Szeged,2002,46(1/2):1-12.
[34]Coelho, Jacob L, Fioamramont J, et al. Rectal antinocicepties properties of alverine citrate are linked to antagonism at the 5-HT1a receptor subtype, JPP,2001,53:1419-1426.
[35]Suzuki R, Rygh LJ, Dickenson AH. Bad news from the brain:descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci,2004,25(12):613-7.
[36]Szewczyk B, Albert PR, Rogaeva A, et al. Decreased expression of Freud-1/CC2D1A, a transcriptional repressor of the 5-HT1A receptor, in the prefrontal cortex of subjects with major depression. Int J Neuropsychopharmacol,2010,13(8):1089-101.
[37]Coelho AM, Jacob L, Fioramonti J, et al. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J Pharm Pharmacol, 2001,53(10):1419-26.
[38]吕红,李骥,陈益,钱家鸣.5-羟色胺1A在肠易激综合征的变化.第七次全国消化病学学术会议论文汇编,139-140.
[39]Ulmann L, Hatcher JP, Hughes JP, et al. Up-regulation of P2X4 receptors in spinal microglia after peripheral nerve injury mediates BDNF release and neuropathic pain. J Neurosci 2008; 28:11263-8.
[40]Groth R, Aanonsen L. Spinal brain-derived neurotrophic factor (BDNF) produces hyperalgesia in normal mice while antisense directed against either BDNF or trkB,prevent inflammation-induced hyperalgesia. Pain 2002,100:171-81.
[41]Obata K,Noguchi K. BDNF in sensory,neurons and chronic pain. Neurosci Res,2006, 55(1):1-10.
[42]赖华梅,诸琦,王静,等.脑源性神经营养因子在乳鼠结肠扩张刺激诱导的慢性内脏高敏感和肠道动力异常中的作用.胃肠病学,2008,13(4)：223-227.
[43]Yu YB, Zuo XL, Zhao QJ, Chen FX, Yang J, Dong YY, Wang P, Li YQ. Brain-derived neurotrophic factor contributes to abdominal pain in irritable bowel syndrome. Gut.2012 May;61(5):685-94.
[44]Rage F, Givalois L, Marmigere F, Tapia-Arancibia L, Arancibia S. Immobilization stress rapidly modulates BDNF mRNA expression in the hypothalamus of adult male rats. Neuroscience,2002,112(2):309-18.
[45]于琦,金光亮.三种复方对慢性应激模型大鼠海马CREB、BDNF基因表达的影响.中国病理生理杂志,2009,25(3)：591-594.
[46]Zhang XJ, Chen HL, Li Z, Zhang HQ, Xu HX, Sung JJ, Bian ZX. Analgesic effect of paeoniflorin in rats with neonatal maternal separation-induced visceral hyperalgesia is mediated through adenosine A(1) receptor by inhibiting the extracellular signal-regulated protein kinase (ERK) pathway. Pharmacol Biochem Behav,2009,94(1):88-97.
[47]Mawe GM, Coates MD, Moses PL. Review article:intestinal serotonin signalling in irritable bowel syndrome. Aliment Pharmacol Ther.2006,23(8):1067-76.
[48]周福生,吴文江,张庆宏.胃肠功能性疾病证型分布的统计分析.中华国际医学杂志,2002,2(5)：438-442.
[49]李晓红,陈家旭.肝主疏泄与脑-肠轴的相关性探讨.中医杂志,2010,51(10)：872-874.
